Enhertu (trastuzumab deruxtecan) first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu…
Tukysa (tucatinib) new option of treatment of adult patients with advanced forms of HER2-positive breast cancer
As part of Project Orbis, the U.S. Food and Drug Administration has approved…
Enhertu (fam-trastuzumab deruxtecan-nxki), new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
The U.S. Food and Drug Administration granted accelerated approval to Enhertu…